Press Releases

EXTON, Pa., Nov. 11 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration. The clearance allows for the use of Medeor Matrix in general surgery for the reinforcement and repair of soft tissue, including hernia repair and plastic and reconstructive surgical applications.

Medeor Matrix is a porcine-based dermal extracellular matrix designed to act as a biologic scaffold to stimulate the deposition of organized tissues specific to an injured site. These ECM products facilitate rapid revascularization and are therefore quickly repopulated with cells from the host tissue and ultimately converted into functional living tissue. Medeor Matrix is manufactured using Kensey Nash's proprietary Optrix(TM) process, which gently disinfects tissues, inactivates viruses and removes cells while preserving extracellular matrix components.

"This regulatory clearance represents an important milestone in our plans to build upon Kensey Nash's leadership position as a developer of innovative regenerative medicine products," commented Doug Evans, Chief Operating Officer of Kensey Nash. "These are the first products developed from our new ECM biologic surgical mesh technology. With Medeor Matrix as a platform product line, we plan to develop additional devices for use in a wide range of soft tissue repair procedures. We expect these efforts to yield new collaborative partners and additional products in the rapidly growing biosurgery market that will provide continued diversification and expansion of our business in the future. As a Company, we are committed to developing unique and effective therapies that address the unmet clinical needs of physicians and patients around the world," he concluded.

The Company had previously announced a strategic agreement with Synthes, Inc. (SWX:SYST.VX), whereby Synthes will market and distribute porcine dermis-based ECM products for select reconstructive surgical applications. Kensey Nash is currently evaluating partnering opportunities for additional applications of the Medeor Matrix products in the urogynecology, wound care, orthopaedic and other markets. The Company anticipates that Medeor Matrix will be introduced into the market for initial indications in the second half of the current fiscal year.

About Kensey Nash Corporation. Kensey Nash Corporation is a leader in developing, manufacturing and processing resorbable biomaterial products, incorporating its proprietary collagen and synthetic polymer technology. This expertise is used to develop and commercialize its products through strategic partners. The company has an extensive range of products, which are sold in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets. The company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release as well as other Company press releases contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received), Spectranetics' success in selling the ThromCat(TM) product, the Company's success in distributing its products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, the Company's success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, Synthes' success in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products and competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

SOURCE Kensey Nash Corporation

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (NASDAQ: BRKR) announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009, at 10:55 AM Eastern Standard Time in New York City. William Knight, Chief Financial Officer, will speak on behalf of the Company. A live audio webcast of this presentation will also be available on the Investor section of the Company's Web site at http://ir.bruker.com. A replay of the presentation will be posted on the Bruker Corporation website after the event and will be available for 30 days following the presentation.

ABOUT BRUKER CORPORATION

For more information about Bruker Corporation, please visit www.bruker.com.

    Source: Bruker Corporation

PALO ALTO, Calif.--(BUSINESS WIRE)-- The Lanier Law Firm, a national litigation firm, is continuing to expand the firm's operations in Palo Alto, Calif., based on a unique, contingency-fee approach to intellectual property cases where clients pay no fees up front, and the firm gets paid only if it wins.

Unlike many law firms that require clients to pay costly expenses and other charges while their cases are being prepared, The Lanier Law Firm is one of the few trial firms in the country that assumes all expenses for experts and case preparation, allowing many deserving patent owners and inventors to assert their legal rights when they otherwise could not afford to.

"Contingency-fee litigation is ideal for many small companies or independent inventors," says firm founder Mark Lanier. "Many of our clients lack the financial resources to protect their intellectual property, and that is where we step in to help."

Patent litigation veteran and Californian Christopher Banys is the Managing Attorney of the firm's Palo Alto office, where he leads the Intellectual Property Litigation Group.

"Our contingency-fee model has been a tremendous success since we opened our office in Palo Alto last year," says Mr. Banys, who previously practiced with the law firm of Howrey LLP. "We are extremely confident in the cases we're handling, and we are committed to helping inventors and companies whose intellectual property rights are infringed, and often stolen."

No stranger to tough cases, Mr. Banys and the firm are taking on such big name defendants as video game giant Nintendo, computer pioneer Apple, and St. Jude Medical, one of the world's leading providers of medical equipment.

To handle the growth of the intellectual property work, the firm has renovated and expanded its Palo Alto offices, which are located at 2200 Geng Road, Suite 200, Palo Alto, California, 94303. The firm is unveiling the newly renovated space during a reception later this month with guests from the local media, technology industry and legal community.

The Palo Alto office is a main hub of the firm's Intellectual Property Litigation Group, which represents clients in disputes involving patent infringement, trademark and copyright violations, unlawful use of trade secrets and other areas of intellectual property law.

With offices in Los Angeles, Palo Alto, Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions in courtrooms across the country. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, intellectual property, business litigation, product liability, toxic exposure and maritime law.

    Source: The Lanier Law Firm

WHAT: Lockheed Martin is hosting an opening ceremony to celebrate its NexGen Cyber Innovation and Technology Center and will also announce a technology Cyber Security Alliance. Built to speed the delivery of cyber innovation through collaboration, the 25,000 square foot facility is a global security asset designed to preserve and protect Lockheed Martin customer missions and address the greater cyber security challenges worldwide.

WHO: Bob Stevens, Lockheed Martin Chairman, President & Chief Executive Officer and Linda Gooden, Executive Vice President, Lockheed Martin IS&GS will host The Honorable Maryland Governor Martin O'Malley, the Honorable Congressman Chris Van Hollen and other notable government officials and technology industry executives to include Art Coviello, Executive Vice President, EMC and President, RSA, the Security Division of EMC.

WHEN: Thursday, November 12, 2009. The event will begin at 10:00 a.m. and conclude by 11:00 a.m. EST. The Center will open at 9:00am.

WHERE: Lockheed Martin, 700 North Frederick Avenue, Gaithersburg, Maryland.

CONTACT:

Lockheed Martin Information Systems & Global Services - Mary Phillips, (240) 252-9425, mary.phillips@lmco.com

For additional information, visit our websites:

http://www.lockheedmartin.com

http://www.lockheedmartin.com/isgs/capabilities/NexGen/

/PRNewswire -- Nov. 11/

SOURCE Lockheed Martin

DECATUR, Ill.--(BUSINESS WIRE)-- Archer Daniels Midland Company (NYSE: ADM) will present at the 2009 Morgan Stanley Global Consumer and Retail Conference in New York on Thursday, Nov. 19, 2009.

Steve Mills, executive vice president and chief financial officer, will present at 3:20 p.m. Eastern Time.

The ADM presentation will be webcast live at www.adm.com/webcast. A replay of the presentation will be available Nov. 20 to Nov. 30, 2009, at www.adm.com/webcast.

About ADM

Every day, the 28,000 people of Archer Daniels Midland Company (NYSE: ADM) turn crops into renewable products that meet the demands of a growing world. At more than 230 processing plants, we convert corn, oilseeds, wheat and cocoa into products for food, animal feed, chemical and energy uses. We operate the world's premier crop origination and transportation network, connecting crops and markets in more than 60 countries. Our global headquarters is in Decatur, Illinois, and our net sales for the fiscal year ended June 30, 2009, were $69 billion. For more information about our Company and our products, visit www.adm.com.

    Source: Archer Daniels Midland Company